SYDNEY, AUSTRALIA and LONDON and NEW CANAAN, CT--(Marketwire - May 09, 2008) - The accrual time for the OVArian TUmor REsponse (OVATURE) clinical study, a Phase III study of the investigational chemosensitizing drug, phenoxodiol, has been extended to facilitate complete patient enrollment in the U.S., Europe, and Australia. Increasing the accrual period allowed decreasing the total number of patients in the study, without changing the required statistical analyses. As a result, the OVATURE study will enroll 340 patients at 60 to 80 clinical sites throughout the United States, Europe, and Australia. Initially, this study was announced to enroll 470 patients.
